 |
|
A Population-Based Study of Bilateral Prophylactic Mastectomy Efficacy in Women at Elevated Risk for Breast Cancer in Community Practices
Ann M. Geiger, PhD;
Onchee Yu, MS;
Lisa J. Herrinton, PhD;
William E. Barlow, PhD;
Emily L. Harris, PhD;
Sharon Rolnick, PhD;
Mary B. Barton, MD;
Joann G. Elmore, MD;
Suzanne W. Fletcher, MD, MSc
Arch Intern Med. 2005;165:516-520.
Background Findings from several studies suggest that bilateral prophylactic mastectomy reduces breast cancer incidence by 90% or more, but the studies used highly selected patients from referral centers, and the comparison groups were not population based. We studied the efficacy of bilateral prophylactic mastectomy in women with elevated breast cancer risk cared for in community practices.
Methods We conducted a retrospective case-cohort study of women aged 18 to 80 years with 1 or more breast cancer risk factors (family history of breast cancer, history of atypical hyperplasia, or  1 breast biopsies with benign findings). Using computerized data and medical records, we identified 276 women with bilateral prophylactic mastectomy and a stratified random sample of 196 women representing an underlying cohort of 666 800 women with elevated breast cancer risk without prophylactic mastectomy, and then we determined who developed breast cancer.
Results Breast cancer developed in 1 woman (0.4%) after bilateral prophylactic mastectomy vs 26 800 women (4.0%) without prophylactic mastectomy. Stratifying by birth year, the hazard ratio for breast cancer occurrence after bilateral prophylactic mastectomy was 0.005 (95% confidence interval, 0.001-0.044). No woman with bilateral prophylactic mastectomy died of breast cancer vs a calculated 0.2% of women without prophylactic mastectomy.
Conclusions Bilateral prophylactic mastectomy reduced breast cancer incidence in women at elevated risk for breast cancer cared for in community-based practices. However, the absolute risk of breast cancer incidence and death in women who did not undergo the procedure in these settings was relatively low.
Author Affiliations: Research and Evaluation Department, Southern California Permanente Medical Group, Pasadena (Dr Geiger); Center for Health Studies, Group Health Cooperative, Seattle, Wash (Ms Yu and Dr Barlow); Division of Research, The Permanente Medical Group, Oakland, Calif (Dr Herrinton); Departments of Biostatistics (Dr Barlow) and Medicine (Dr Elmore), University of Washington, Seattle; Center for Health Research, Kaiser Permanente Northwest, Portland, Ore (Dr Harris); HealthPartners Research Foundation, Minneapolis, Minn (Dr Rolnick); Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care, Boston, Mass (Drs Barton and Fletcher); and Cancer Research and Biostatistics, Seattle (Dr Barlow).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Women at High Risk for Breast Cancer--What the Primary Care Provider Needs to Know
Afonso
J Am Board Fam Med 2009;22:43-50.
ABSTRACT
| FULL TEXT
Reshaping Cancer Learning Through The Use Of Health Information Technology
Wallace
Health Aff (Millwood) 2007;26:w169-w177.
ABSTRACT
| FULL TEXT
Is Routine Sentinel Lymph Node Biopsy Indicated in Women Undergoing Contralateral Prophylactic Mastectomy? Magee-Womens Hospital Experience
Soran et al.
Ann. Surg. Oncol. 2007;14:646-651.
ABSTRACT
| FULL TEXT
Quality of Life After Bilateral Prophylactic Mastectomy
Geiger et al.
Ann. Surg. Oncol. 2007;14:686-694.
ABSTRACT
| FULL TEXT
Building a Virtual Cancer Research Organization
Hornbrook et al.
J Natl Cancer Inst Monogr 2005;2005:12-25.
ABSTRACT
| FULL TEXT
Complications Following Bilateral Prophylactic Mastectomy
Barton et al.
J Natl Cancer Inst Monogr 2005;2005:61-66.
ABSTRACT
| FULL TEXT
Race and Ethnicity: Comparing Medical Records to Self-Reports
West et al.
J Natl Cancer Inst Monogr 2005;2005:72-74.
ABSTRACT
| FULL TEXT
Prophylactic Mastectomy for Women at Elevated Risk: More Evidence of Efficacy
JWatch Women's Health 2005;2005:2-2.
FULL TEXT
|
